Drugs / Cam2020 M2SR
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05163847 | Jun → Nov 2022 | — | FluGen Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cam2020 M2SR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05163847 ↗ |
| Known as | M2SR | “the intranasal H3N2 M2-deficient single-replication (M2SR) vaccine” PMID 39004096 ↗ Jul 2024 |
| Modality | Vaccine | “the intranasal H3N2 M2-deficient single-replication (M2SR) vaccine” PMID 39004096 ↗ Jul 2024 |
| Route | Intranasal | “Administered intranasally on Day 1” NCT05163847 ↗ |